Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Known or highly suspected central nervous system (CNS) pathology referred for contrast-enhanced MRI of the CNS.~* Glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m2 derived from a serum creatinine result within four weeks prior to the first study MRI.~* Women with negative urine pregnancy test within 1 hour prior to the administration of gadoterate (the first MRI).~Exclusion Criteria:~* No enhancing lesion visible on the gadoterate-enhanced MRI scan.~* Pregnancy or breastfeeding.~* Severe cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1_Suspected CNS-lesion (Type: EXPERIMENTAL): Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
- Arm 2_Confirmed CNS-lesion (Type: EXPERIMENTAL): Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).